Evommune, Inc. (EVMN) income statement
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$6.88−0.14 (-1.99%)
Close on Nov 18, 2026Market cap $249.69MP/E –Yield –
Evommune, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -224.6%
Financial strength
- Current ratio
- 8.52
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 232.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.99
- Dividend yield
- –
See a number that looks wrong?